Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.
Hypertension is one of the many comorbidities that plagues gout patients.
Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.
David Liew drdavidliew
7 years 3 months ago
Good lessons from 22,607 RA patients from the UK CPRD: cataracts and glaucoma from pred are dose dependent, and even 1000mg cumulative dose is enough. That’s equivalent to three months PMR therapy for most #EULAR2019 SAT0592 @dr_rachelblack @CatherineL_Hill @earlyARA @RheumNow https://t.co/AJfBgLdHdb
Dr. John Cush RheumNow
7 years 3 months ago
Dr. Peter Lipsky - 1 Million #Gout Patients & who cares for them. SAT0435 #EULAR2018 https://t.co/WfFR4tRf2p
Dr. John Cush RheumNow
7 years 3 months ago
14 patient pilot study presented by Dr. Genovese; once daily vagal stimulation worked but 4 times daily did not! https://t.co/TUWr7fT7x3
Alberta Hoi tuna0sashimi
7 years 3 months ago
FUTURE 5 secukinumab in PsA placebo arm only 12w. Week 52 pt can increase doses from 150mg to 300mg. 2y data presented. Small incremental response when dose is escalated, and radiographic progression is low. #eular2019 @RheumNow
Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rheumatic and Musculoskeletal Medicine presented at EULAR 2019.
Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. It was a full and lively second day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day two at EULAR 2019.
Dr. John Cush RheumNow
7 years 3 months ago
Men with #gout are severely under treated, under educated and unmotivated to better manage their gout! https://t.co/icdDIUSdJb
Dr. John Cush RheumNow
7 years 3 months ago
Dr. Dinesh Khanna discusses the pulmonary outcomes of tocilizumab is systemic sclerosis (focuSSed trial). #EULAR2019 OP0245 https://t.co/UtvBLz6Cg7 https://t.co/tptDVbBug2
Dr. John Cush RheumNow
7 years 3 months ago
#EULAR2019 Emapalumab - a monoclonal Ab against IFNγ - was shown to be effective in 6 systemic JIA (Stills) patients with macrophage activation syndrome. Rx led to rapid neutralization of IFNγ, normalization of CXCL9, & decreased T cell activation. OP0204 https://t.co/9mtxPkHZr3
David Liew drdavidliew
7 years 3 months ago
We need to talk about repeated ANAs - good lessons from the plenary hall today about 7875 repeated ANA tests from a single center. #EULAR2019 OP0020 by Ai Li Yeo @RheumNow @MonashHealth @earlyARA @ChooseWiselyAU https://t.co/j00DDKuZFt
Editor's note: July 1 - 5, RheumNow is running the best of EULAR 2019 meeting. Hydroxychloroquine (HCQ) will decrease SLE flares improve lipids, decrease clots, improve survival, augment the response to mycophenolate and are the cornerstone of treatment as per the SLE EULAR guidelines presented at EULAR 2019 in Madrid and also published in ARD. But, if you prescribe them long term, will your patients go blind?
Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Here are a few of the highlights from day 1 EULAR in Madrid, including another IL-23 inhibitor, BTK inhibition, abatacept in Sjogren's syndrome, don't repeat the ANA, and drug free remission in systemic JIA.
Dr. John Cush RheumNow
7 years 3 months ago
795 RA patients from the GIRRCS cohort 3 yr study found that maintaining remission reduced the incidence of subclinical atherosclerosis by three-quarters (OR = 0.25; P = .001). (87% were on MTX; 60% on biologics) #EULAR2019 ABST# OP0090 https://t.co/RvRcXsDnKs
